Hospital
Hospital Development Co
Hospital Development Co was paid $14.56M by Medicaid between Jan 2018 and Dec 2024, across 146 billing codes. Its largest line is 99285, emergency room visit (most serious) — 15% of everything it billed.
33Billing provider infoHOSPITAL DEVELOPMENT CO
SPENCER, WV 25276
SPENCER, WV 25276
33aNPI1316907322assigned 03/24/2006
33bProvider typeCritical Access Hospital
28Total paid$14.56M
24GClaims226,136
24DCodes billed146
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in West Virginia
Rank by total paid#4 of 24
Median peer was paid$3.57M
This provider vs. median4.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,996 | $3.30M | |
| 2019 | 29,108 | $2.12M | |
| 2020 | 43,369 | $2.78M | |
| 2021 | 40,689 | $2.39M | |
| 2022 | 32,059 | $1.29M | |
| 2023 | 26,977 | $1.47M | |
| 2024incomplete | 17,938 | $1.20M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 7,593 | 5,359 | $2.11M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 6,604 | 5,308 | $1.46M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.8% | 5,147 | 4,380 | $840K |
| 80053 | Comprehensive metabolic panel | 4.2% | 11,907 | 9,836 | $607K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.0% | 1,407 | 1,253 | $576K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 1,381 | 1,210 | $402K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.7% | 2,751 | 2,487 | $392K |
| 87631 | 2.6% | 5,119 | 3,858 | $373K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 12,661 | 9,231 | $358K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 6,420 | 1,685 | $325K |
| 36415 | Collection of venous blood by venipuncture | 2.1% | 21,202 | 15,953 | $311K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 2,394 | 1,972 | $289K |
134 more codes
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.9% | 1,337 | $283K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 4,335 | $272K |
| J3490 | Unclassified drugs | 1.8% | 6,011 | $258K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 630 | $257K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 6,443 | $248K |
| 83605 | 1.4% | 4,976 | $207K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,657 | $196K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.3% | 907 | $188K |
| 84484 | 1.3% | 5,120 | $186K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 5,167 | $185K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 2,040 | $177K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 2,346 | $161K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,236 | $138K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,802 | $137K |
| 81001 | <1% | 5,441 | $137K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,423 | $127K |
| 85027 | <1% | 3,560 | $126K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,763 | $125K |
| 80061 | Lipid panel | <1% | 2,270 | $122K |
| 64483 | <1% | 162 | $103K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 127 | $98K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,470 | $95K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,820 | $93K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,281 | $84K |
| G0378 | Hospital observation service, per hour | <1% | 419 | $84K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,067 | $81K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,674 | $75K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,844 | $73K |
| A9270 | Non-covered item or service | <1% | 26,926 | $72K |
| 96376 | <1% | 748 | $71K | |
| 83735 | <1% | 2,002 | $68K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 105 | $67K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 859 | $65K |
| 83690 | <1% | 1,809 | $65K | |
| 93017 | <1% | 197 | $61K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 518 | $59K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 105 | $58K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,822 | $55K |
| 87040 | <1% | 821 | $55K | |
| 71250 | <1% | 172 | $53K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 468 | $50K |
| 80305 | <1% | 730 | $49K | |
| 84703 | <1% | 951 | $49K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 216 | $44K |
| 73030 | <1% | 427 | $42K | |
| 87081 | <1% | 1,318 | $41K | |
| 74178 | <1% | 99 | $41K | |
| 73630 | <1% | 361 | $38K | |
| 73610 | <1% | 382 | $38K | |
| 74019 | <1% | 232 | $37K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,581 | $37K |
| 87186 | <1% | 975 | $36K | |
| 82948 | <1% | 835 | $36K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 539 | $35K |
| 87077 | <1% | 1,201 | $35K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,696 | $35K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 227 | $34K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 806 | $34K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 742 | $33K |
| 85610 | <1% | 1,248 | $33K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 149 | $32K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,425 | $31K |
| 84439 | <1% | 678 | $31K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,945 | $30K |
| 97162 | <1% | 466 | $29K | |
| 72100 | <1% | 226 | $29K | |
| J2400 | Injection, chloroprocaine hydrochloride, per 30 ml | <1% | 127 | $27K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 610 | $27K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,045 | $22K |
| 82607 | <1% | 325 | $22K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 937 | $22K |
| 83880 | <1% | 416 | $21K | |
| 73560 | <1% | 194 | $21K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 313 | $20K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 83 | $20K |
| J2704 | Injection, propofol, 10 mg | <1% | 912 | $20K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 395 | $19K |
| 85379 | <1% | 485 | $18K | |
| 87070 | <1% | 376 | $17K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 427 | $17K |
| 73110 | <1% | 129 | $15K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 276 | $14K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 72 | $11K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 996 | $11K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 576 | $9K |
| 82805 | <1% | 158 | $7K | |
| 82150 | <1% | 91 | $7K | |
| 80050 | General health panel | <1% | 48 | $7K |
| 73130 | <1% | 69 | $7K | |
| 36600 | <1% | 164 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 67 | $6K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 60 | $6K |
| 94060 | <1% | 80 | $6K | |
| 87205 | <1% | 133 | $5K | |
| 87807 | <1% | 58 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 187 | $5K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 53 | $5K |
| 0012A | <1% | 200 | $4K | |
| 73502 | <1% | 28 | $4K | |
| 0011A | <1% | 264 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $3K |
| 87430 | <1% | 33 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $3K |
| 94727 | <1% | 51 | $3K | |
| 82043 | <1% | 60 | $3K | |
| 86769 | <1% | 49 | $2K | |
| 73521 | <1% | 13 | $2K | |
| 94729 | <1% | 52 | $2K | |
| 86318 | <1% | 25 | $2K | |
| 83540 | <1% | 51 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 18 | $2K |
| 94664 | <1% | 24 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 15 | $2K |
| 82728 | <1% | 42 | $2K | |
| 0013A | <1% | 62 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 33 | $1K |
| 85652 | <1% | 32 | $1K | |
| Q3014 | Telehealth originating site facility fee | <1% | 61 | $1K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 15 | $1K |
| 74022 | <1% | 15 | $1K | |
| 94200 | <1% | 53 | $956.74 | |
| 94150 | <1% | 53 | $753.03 | |
| 84145 | <1% | 14 | $698.43 | |
| 82800 | <1% | 15 | $698.31 | |
| 0001A | <1% | 35 | $591.55 | |
| 0072A | <1% | 20 | $490.40 | |
| 82550 | <1% | 22 | $369.34 | |
| 0071A | <1% | 14 | $325.60 | |
| 86901 | <1% | 15 | $122.18 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 83 | $94.39 |
| 91301 | <1% | 662 | $16.60 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 44 | $4.68 |
| 91300 | <1% | 96 | $0.43 | |
| 91307 | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBENTZ, DOUG (CEO)
| Provider | Location | Paid |
|---|---|---|
| Hospital Development Co | Spencer, WV | $10.11M |
| Hospital Development Co | Spencer, WV | $7.52M |
| Hospital Development Co | Left Hand, WV | $1.06M |
| Hospital Development Co | Spencer, WV | $727K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.